Combination Therapy for Imatinib-Resistant CML Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic myeloid leukemia (CML), particularly imatinib mesylate (IM)-resistant cases, face challenges due to BCR-ABL-independent resistance mechanisms, where CML stem cells exhibit intrinsic resistance to IM, hindering long-term treatment and cure prospects.
Innovation Solution
Combining a BCR-ABL inhibitor, such as imatinib, with a MEK inhibitor, like trametinib, to target and synergistically kill CML stem cells, while minimizing effects on normal hematopoietic cells, using a therapeutic approach that involves detecting elevated PRKCH mRNA or PKCeta protein levels to select appropriate treatment subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imatinib mesylate (IM) is used to treat CML, then patient survival is dramatically improved in early-stage disease, but resistance develops especially in advanced-stage disease leading to relapse and progression
Solution Approach 1:
The patent combines IM with a MEK inhibitor to create a dual-target therapy that simultaneously blocks BCR-ABL signaling and MEK/ERK signaling pathways. This combination approach addresses both BCR-ABL-dependent and BCR-ABL-independent resistance mechanisms, thereby improving long-term treatment sustainability while maintaining initial effectiveness.
Solution Approach 2:
The patent changes the therapeutic parameter from single-target inhibition to dual-pathway inhibition by adding MEK inhibitor to the standard IM regimen. This parameter change allows the treatment to overcome resistance mechanisms that single-agent IM cannot address, particularly in advanced-stage disease.
2Reliability
If IM is used to treat CML, then early-stage disease response is achieved, but BCR-ABL-independent resistance mechanisms cause intrinsic resistance in CML stem cells
Solution Approach 1:
The patent merges BCR-ABL inhibition with MEK inhibition to create a therapy that addresses multiple resistance pathways simultaneously. The MEK inhibitor component specifically targets BCR-ABL-independent resistance mechanisms, including those active in CML stem cells, thereby improving adaptability to various resistance scenarios while preserving initial response rates.
Solution Approach 2:
The patent segments the resistance problem into two distinct pathways: BCR-ABL-dependent resistance (addressed by IM) and BCR-ABL-independent resistance (addressed by MEK inhibitor). This segmentation allows each agent to target its specific mechanism, improving overall versatility against diverse resistance types.
3Reliability
If combination treatment with IM and MEK inhibitor is used, then CML stem cells are synergistically killed, but treatment complexity increases
Solution Approach 1:
The patent combines two targeted therapies into a unified treatment regimen that achieves synergistic killing of CML stem cells. While this increases treatment complexity, it also dramatically improves curative potential by addressing both proliferating leukemic cells and quiescent stem cells through different mechanistic pathways.
Data Source
AI summary
Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.